7 A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

8 Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses

9 Immunological responses to monoassociated Bifidobacterium longum and their relation to prevention of bacterial invasion

10 Validation of immunoglobulin G enzyme-linked immunosorbent assay for antibodies to pneumococcal surface adhesin A in the diagnosis of pneumococcal pneumonia among adults in Kenya

11 Certolizumab pegol for induction of remission in Crohn's disease

12 Human tularemia in France, 2006-2010

13 Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

14 Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus

15 Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration

16 Impaired humoral response to vaccines among HIV-exposed uninfected infants

17 Immunodetection of pneumolysin in human urine by ELISA

18 Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers

19 Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants

20 Immunological effects of HIV-1 infection on the humoral response to malaria in an African population

21 Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals

22 Augmented antibody response to live attenuated measles vaccine in children with Plasmodium falciparum parasitaemia

23 Reinfection of mice with respiratory syncytial virus

24 Single point quantification of antibody by ELISA without need of a reference curve

25 Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons

26 Diagnosis of invasive pneumococcal disease among children in Kenya with enzyme-linked immunosorbent assay for immunoglobulin G antibodies to pneumococcal surface adhesin A

27 Measles vaccination in severely malnourished Sudanese children

28 Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis

29 Epidemiology of respiratory syncytial virus infection among infants and children in Chicago

30 Effects of maternal and infant co-infections, and of maternal immunisation, on the infant response to BCG and tetanus immunisation

31 The acquisition of herpes simplex virus during pregnancy

32 Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial

33 Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin

34 Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice

35 Systemic cell-mediated and antibody responses in infants with respiratory syncytial virus infections

36 Age related IgG subclass response to respiratory syncytial virus fusion protein in infected infants

37 Pneumococcal immune complexes in the diagnosis of lower respiratory infections in children

38 First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial

39 Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model

40 Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses

41 Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60

42 Lymphocyte subpopulations and antibody levels in immunized malnourished children

43 Herpes simplex virus type 2 in the United States, 1976 to 1994

44 Neonatal measles immunity in rural Kenya: the influence of HIV and placental malaria infections on placental transfer of antibodies and levels of antibody in maternal and cord serum samples

45 Effect of ribavirin therapy on respiratory syncytial virus-specific IgE and IgA responses after infection

46 Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial

47 Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly

48 Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies

49 An appraisal of screening for maternal type-specific herpes simplex virus antibodies to prevent neonatal herpes

50 Development of cell-mediated cytotoxic immunity to respiratory syncytial virus in human infants following naturally acquired infection

51 The immune response to a meningococcal polysaccharide vaccine in an African village

52 The psychosocial impact of testing individuals with no history of genital herpes for herpes simplex virus type 2

53 Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi

54 Enzyme-linked immunosorbent assay for measurement of serological response to respiratory syncytial virus infection

55 The immunologic response to infection with respiratory syncytial virus in infants

56 Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein

57 Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis

58 Immunopathologic mechanisms in lower respiratory tract disease of infants due to respiratory syncytial virus

59 Protein energy malnutrition decreases immunity and increases susceptibility to influenza infection in mice

60 Vedolizumab for induction and maintenance of remission in ulcerative colitis

61 Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis

62 Loss of cellular immune reactivity during acute Plasmodium falciparum malaria

63 Effectiveness of measles vaccine given simultaneously with DTP

64 Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection

65 The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection

66 The laboratory confirmation of suspected measles cases in settings of low measles transmission: conclusions from the experience in the Americas

67 Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine

68 Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment

69 Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

70 The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants

71 Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections

72 Prolactin has a pathogenic role in systemic lupus erythematosus

73 Hemophagocytosis in dengue: comprehensive report of six cases

74 The immunological response to polyvalent meningococcal vaccine in Bauchi State, Nigeria

75 Immune response to Bordetella pertussis is associated with season and undernutrition in Senegalese children

76 Respiratory syncytial virus infection in anti-mu-treated mice

77 Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus (RSV) is associated with a significant reduction in pulmonary RSV replication

78 Differences in the immune response to hepatitis B and Haemophilus influenzae type b vaccines in Guatemalan infants by ethnic group and nutritional status

79 Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life

80 Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh

81 Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus

82 Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers

83 Comparative virulence of respiratory syncytial virus subgroups A and B

84 Malnutrition and seroconversion following measles immunization

85 Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children

86 Vedolizumab as induction and maintenance therapy for ulcerative colitis

87 Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat

88 Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination

89 Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

90 Local antibody production and respiratory syncytial virus infection in children with leukaemia

91 Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals

92 Risk factors for the sexual transmission of genital herpes

93 Virus-specific IgE and IgG4 antibodies in serum of children infected with respiratory syncytial virus

94 Pathogenesis of bronchiolitis--epidemiologic considerations

95 Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection

96 Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells

97 Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement

98 The role of TH1 and TH2 cells in a rodent malaria infection

99 An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines

100 Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men

101 Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant

Keyword Connections

Journals

Research Groups

Bibliographies